China channel feed – Endpoints News

China channel feed

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene is one step closer to China OK for PD-1

6 years ago

ARCH-backed Chinese biotech scores PhIII win for glucokinase-modulating diabetes drug

6 years ago

Tot Biopharm completes HKEX listing, raising $63M in modest debut

6 years ago

Alzheimer's breakthrough? Not so fast — experts poke holes in data underlying China's surprise approval

6 years ago

AstraZeneca sketches plans for a $1B venture fund — and it's going to China

6 years ago

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

6 years ago

Alzheimer's stunner: Chinese biotech wins OK for a new drug on positive data — and they have some high-profile supporters

6 years ago

Amgen takes a $2.7B stake in BeiGene, gaining a prominent ally in China to help seize a leading role in cancer drug commercialization and development

6 years ago

In a bid to get to Chinese patients faster, Shanghai's I-Mab plans $100M Nasdaq IPO

6 years ago

Ascentage soars during its first day on the Hong Kong exchange, following $53M debut

6 years ago

China's Fountain Medical scores $62M as demand for CRO services surges

6 years ago

Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there

6 years ago

Following top-level C-suite departures, Ascletis raids Novartis for R&D exec

6 years ago

San Diego couple charged with stealing trade secrets, opening Chinese biotech as DOJ crackdown continues

6 years ago

Cancer drugs among US goods spared from tariffs as China issues first exemptions in trade war

6 years ago

How about a $477M biotech IPO amid Hong Kong protests? Henlius will find out

6 years ago

Hong Kong strife holds up almost $100M of BioNTech's Series B haul

6 years ago

Private equity meets China biotech: PAG infuses $540M to gain control of Hisun's biosimilar subsidiary

6 years ago

Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent

6 years ago

Biotech leaders rally behind Chinese scientists in US, calls for 'measured' policies in wake of purges

6 years ago

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications

6 years ago

Preferential tax policies coming for biopharmas setting up shop in Shanghai's newest free trade zone

6 years ago

Move over, Hong Kong: Shanghai’s new tech board sees fervent demand for maiden biotech IPO

6 years ago

Following footsteps of chart-topping Chinese counterparts, Alphamab Oncology files IPO at HKEX

6 years ago

First page Previous page 19 20 212223 24 25 Next page Last page